Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN C HUANG

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1487711743
CMS profile
519575
Location
ROCHESTER, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$489.00

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $312.96 1
Education $176.04 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Dentsply Sirona Inc $489.00 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN C HUANG

NPI 1487711743 · CMS profile ID 519575

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ROCHESTER, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487711743?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN C HUANG, NPI 1487711743, CMS profile ID 519575. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487711743?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JONATHAN C HUANG, NPI 1487711743, CMS profile ID 519575. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487711743?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JONATHAN C HUANG, NPI 1487711743, CMS profile ID 519575, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1487711743?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $489.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dentsply Sirona Inc $312.9609/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123501948 CMS
Dentsply Sirona Inc $176.0409/26/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123501950 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $823.09 4
PY2024 $489.00 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $32,934.00 6
PY2024 Principal investigator $40,978.44 6
PY2023 Principal investigator $42,310.71 13
PY2022 Principal investigator $39,710.83 17
PY2021 Principal investigator $133,754.01 45
PY2020 Principal investigator $136,974.55 43
PY2019 Principal investigator $205,229.73 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Intercept Pharmaceuticals, Inc. $842.40 12/19/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062058
Principal investigator 1 Gilead Sciences, Inc. $1,080.00 12/18/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676488037
Principal investigator 1 Intercept Pharmaceuticals, Inc. $8,109.45 12/18/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702062053
Principal investigator 1 Intercept Pharmaceuticals, Inc. $775.12 12/11/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011507 No dispute reported 06/30/2026 702062048
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,827.54 12/05/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062041
Principal investigator 1 Intercept Pharmaceuticals, Inc. $791.90 11/25/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702062035
Principal investigator 1 Gilead Sciences, Inc. $29,734.00 11/20/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676488033
Principal investigator 1 Intercept Pharmaceuticals, Inc. $13,808.00 11/13/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702062023
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,477.00 11/13/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702062029
Principal investigator 1 Gilead Sciences, Inc. $3,910.00 10/23/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676488023
Principal investigator 1 Gilead Sciences, Inc. $4,194.00 10/23/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676488029
Principal investigator 1 Intercept Pharmaceuticals, Inc. $819.00 10/23/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062019
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,628.30 10/17/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702062009
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,905.00 10/17/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702062013
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,554.54 10/09/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062003
Principal investigator 1 Gilead Sciences, Inc. $1,510.00 10/02/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676488007
Principal investigator 1 Gilead Sciences, Inc. $7,165.97 10/02/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676488013
Principal investigator 1 Gilead Sciences, Inc. $9,571.80 10/02/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676488017
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,709.60 09/19/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702062001
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,618.46 08/27/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702061997
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,254.35 08/22/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702061991
Principal investigator 1 Gilead Sciences, Inc. $52.00 08/21/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676488003
Principal investigator 1 Gilead Sciences, Inc. $1,450.00 08/19/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487989
Principal investigator 1 Gilead Sciences, Inc. $1,450.00 08/19/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487995
Principal investigator 1 Gilead Sciences, Inc. $2,909.00 08/19/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676487997
Principal investigator 1 Intercept Pharmaceuticals, Inc. $564.52 08/15/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011507 No dispute reported 06/30/2026 702061985
Principal investigator 1 Gilead Sciences, Inc. $3,314.00 08/12/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487983
Principal investigator 1 Intercept Pharmaceuticals, Inc. $6,459.96 07/24/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702061979
Principal investigator 1 Gilead Sciences, Inc. $52.00 07/17/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676487971
Principal investigator 1 Gilead Sciences, Inc. $504.00 07/17/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487975
Principal investigator 1 Gilead Sciences, Inc. $1,129.00 07/17/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487980
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,251.66 07/11/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011507 No dispute reported 06/30/2026 702061973
Principal investigator 1 Gilead Sciences, Inc. $6,300.00 07/01/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676487967
Principal investigator 1 Gilead Sciences, Inc. $1,173.00 06/19/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487963
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,338.48 06/19/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702061965
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,944.15 06/18/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702061957
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,347.02 05/27/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702061951
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,344.85 05/23/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702061945
Principal investigator 1 Gilead Sciences, Inc. $1,129.00 05/22/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487959
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,023.00 05/14/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011507 No dispute reported 06/30/2026 702061937
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,167.08 05/09/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011507 No dispute reported 06/30/2026 702061931
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,495.96 04/26/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702061923
Principal investigator 1 Gilead Sciences, Inc. $2,258.00 04/22/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487949
Principal investigator 1 Gilead Sciences, Inc. $8,283.00 04/22/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487955
Principal investigator 1 Gilead Sciences, Inc. $3,520.00 04/17/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487943
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,901.25 04/15/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702061917
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,554.54 04/05/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702061909
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,631.85 03/26/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011866 No dispute reported 06/30/2026 702061901
Principal investigator 1 Gilead Sciences, Inc. $1,129.00 03/20/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487939
Principal investigator 1 Gilead Sciences, Inc. $961.00 03/18/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487930
Principal investigator 1 Gilead Sciences, Inc. $1,922.00 03/18/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487933
Principal investigator 1 Intercept Pharmaceuticals, Inc. $350.00 03/14/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011507 No dispute reported 06/30/2026 702061889
Principal investigator 1 Intercept Pharmaceuticals, Inc. $7,688.46 02/26/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1009742 No dispute reported 06/30/2026 702061879
Principal investigator 1 Gilead Sciences, Inc. $5,614.00 02/20/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487925
Principal investigator 1 Gilead Sciences, Inc. $33.00 01/28/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487901
Principal investigator 1 Gilead Sciences, Inc. $1,129.00 01/28/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676487905
Principal investigator 1 Gilead Sciences, Inc. $5,804.00 01/28/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487915
Principal investigator 1 Gilead Sciences, Inc. $6,201.00 01/28/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487919
Principal investigator 1 Intercept Pharmaceuticals, Inc. $564.52 01/10/2019 Covered Recipient Teaching Hospital
STRONG MEMORIAL HOSPITAL
1011507 No dispute reported 06/30/2026 702061875